2018 Q4 Form 10-Q Financial Statement

#000155198618000049 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.730M $8.110M $170.0K
YoY Change 1232.56% 4670.59% -94.28%
Cash & Equivalents $5.729M $8.112M $1.479M
Short-Term Investments
Other Short-Term Assets $680.0K $530.0K $260.0K
YoY Change 1260.0% 103.85% -40.91%
Inventory $500.0K
Prepaid Expenses
Receivables $130.0K
Other Receivables $0.00
Total Short-Term Assets $6.414M $8.637M $1.060M
YoY Change 752.63% 714.84% -82.7%
LONG-TERM ASSETS
Property, Plant & Equipment $35.10K $40.23K
YoY Change -13.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K $10.00K
YoY Change 0.0% -44.2% 0.0%
Total Long-Term Assets $40.68K $45.81K $2.330M
YoY Change -12.12% -98.03% -5.44%
TOTAL ASSETS
Total Short-Term Assets $6.414M $8.637M $1.060M
Total Long-Term Assets $40.68K $45.81K $2.330M
Total Assets $6.454M $8.683M $3.390M
YoY Change 708.3% 156.14% -60.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.619M $2.883M $620.0K
YoY Change 36.11% 364.98% 59.79%
Accrued Expenses $826.3K $229.4K $1.510M
YoY Change -29.99% -84.81% -53.89%
Deferred Revenue
YoY Change
Short-Term Debt $5.200M $5.190M $1.380M
YoY Change 282.35% 276.09% 3350.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.11M $8.302M $4.880M
YoY Change -22.04% 70.13% -11.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.11M $8.302M $4.880M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $10.11M $8.300M $4.880M
YoY Change 281.63% 70.08% -11.91%
SHAREHOLDERS EQUITY
Retained Earnings -$43.52M -$39.30M
YoY Change 124.85%
Common Stock $2.609K $2.598K
YoY Change -78.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.659M $380.8K -$1.490M
YoY Change
Total Liabilities & Shareholders Equity $6.454M $8.683M $3.390M
YoY Change 708.3% 156.14% -60.54%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26071244 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Trading Symbol
TradingSymbol
INNT
innt Accrued Interest On Note Payable
AccruedInterestOnNotePayable
0 USD
innt Accrued Interest On Note Payable
AccruedInterestOnNotePayable
150000 USD
innt Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents
913000 USD
innt Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents
913000 USD
innt Proceeds From Shortterm Convertible Debt
ProceedsFromShorttermConvertibleDebt
4284999 USD
innt Proceeds From Shortterm Convertible Debt
ProceedsFromShorttermConvertibleDebt
345000 USD
innt Convertible Promissory Notesbeneficial Conversion Feature
ConvertiblePromissoryNotesbeneficialConversionFeature
0 USD
CY2018Q3 innt Capital Stock Authorized
CapitalStockAuthorized
360000000 shares
innt Convertible Promissory Notesbeneficial Conversion Feature
ConvertiblePromissoryNotesbeneficialConversionFeature
3077887 USD
innt Receivable For Warrants Exercised
ReceivableForWarrantsExercised
0 USD
innt Receivable For Warrants Exercised
ReceivableForWarrantsExercised
87152 USD
dei Entity Registrant Name
EntityRegistrantName
INNOVATE BIOPHARMACEUTICALS, INC.
innt Repayments Of Shortterm Convertible Debt
RepaymentsOfShorttermConvertibleDebt
0 USD
innt Repayments Of Shortterm Convertible Debt
RepaymentsOfShorttermConvertibleDebt
275000 USD
CY2018Q1 innt Exchange Ratio In Connection With Merger
ExchangeRatioInConnectionWithMerger
0.37686604
innt Placement Agent Fees
PlacementAgentFees
1600000 USD
innt Proceeds From Rececived Of Payment Of Stock Subscription Receivable
ProceedsFromRececivedOfPaymentOfStockSubscriptionReceivable
25 USD
innt Proceeds From Rececived Of Payment Of Stock Subscription Receivable
ProceedsFromRececivedOfPaymentOfStockSubscriptionReceivable
0 USD
CY2016 innt Milestone Fee Free Sales Target Value
MilestoneFeeFreeSalesTargetValue
1500000000 USD
innt Net Proceeds From Issuance Of Common Stock After Deducting Stock Issuance Costs
NetProceedsFromIssuanceOfCommonStockAfterDeductingStockIssuanceCosts
16500000 USD
innt Number Of Warrants Issued
NumberOfWarrantsIssued
1400000 shares
CY2017Q4 innt Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
60000 USD
CY2017Q4 innt Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
5000 USD
innt Payment Of Deferred Debt Issuance Cost
PaymentOfDeferredDebtIssuanceCost
0 USD
innt Payment Of Deferred Debt Issuance Cost
PaymentOfDeferredDebtIssuanceCost
159795 USD
CY2017 innt Payment Of Stock Subscription Receivable
PaymentOfStockSubscriptionReceivable
25 USD
CY2018Q1 innt Payments To Executives
PaymentsToExecutives
1100000 USD
innt Payments To Executives
PaymentsToExecutives
145000 USD
innt Royalties Payment Expiration Requirement
RoyaltiesPaymentExpirationRequirement
P10Y
innt Stock Issued During Period Value Stock Splits
StockIssuedDuringPeriodValueStockSplits
-978674 USD
innt Warrant Term
WarrantTerm
P5Y
innt Warrants Issued To Placement Agents
WarrantsIssuedToPlacementAgents
0 USD
innt Warrants Issued To Placement Agents
WarrantsIssuedToPlacementAgents
913000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2658637 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2882876 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1180225 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
229401 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0 USD
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7167189 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40879119 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3077887 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6018732 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5055000 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2568079 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1995000 USD
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2000000 USD
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1276934 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4749834 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-3131000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5055000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
29174 USD
CY2018Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
900000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2060000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2100000 USD
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6509824 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6509824 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9391284 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9391284 shares
CY2017Q4 us-gaap Assets
Assets
798489 USD
CY2018Q3 us-gaap Assets
Assets
8683077 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
752202 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
8637264 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360811 USD
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11888240 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25983538 shares
CY2017Q4 us-gaap Cash
Cash
355563 USD
CY2018Q3 us-gaap Cash
Cash
8111682 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1478831 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
355563 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8111682 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1118020 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7756119 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11888240 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25983538 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
11888 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
2598 USD
CY2017Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
8329045 USD
CY2018Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
159795 USD
CY2018Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 USD
us-gaap Depreciation
Depreciation
2522 USD
us-gaap Depreciation
Depreciation
14417 USD
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
75000 USD
CY2018Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1065225 USD
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
0 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1973256 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6115088 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1565992 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9865455 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2451315 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9229513 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-775930 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21147226 USD
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1067247 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-754435 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3311 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-878181 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
40443 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
363738 USD
CY2017Q3 us-gaap Interest Expense
InterestExpense
110508 USD
us-gaap Interest Expense
InterestExpense
281638 USD
CY2018Q3 us-gaap Interest Expense
InterestExpense
1038014 USD
us-gaap Interest Expense
InterestExpense
5593751 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
252464 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
25578 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
280287 USD
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
560380 USD
CY2018Q3 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
0 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
42431 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
127560 USD
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-09-30
CY2017Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
798489 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8683077 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
978674 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12973103 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8302277 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4285024 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20455760 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1600 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61057 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3165404 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12760698 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2451315 USD
us-gaap Net Income Loss
NetIncomeLoss
-9229513 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-11605817 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-775930 USD
us-gaap Net Income Loss
NetIncomeLoss
-21147226 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-110508 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-281638 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-995583 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5466191 USD
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2018Q3 us-gaap Notes Payable Current
NotesPayableCurrent
5190000 USD
CY2017Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
244816 USD
CY2018Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
2340807 USD
us-gaap Operating Expenses
OperatingExpenses
8947875 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
-219653 USD
us-gaap Operating Expenses
OperatingExpenses
15681035 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2340807 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8947875 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-219653 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
15681035 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000 USD
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
91401 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2018Q3 us-gaap Payment For Management Fee
PaymentForManagementFee
1100000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
20000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1495284 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1600 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13943 USD
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
161844 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
525582 USD
us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
0 USD
us-gaap Proceeds From Collection Of Longterm Loans To Related Parties
ProceedsFromCollectionOfLongtermLoansToRelatedParties
75000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18100000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18132661 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
928178 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40707 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40233 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
367551 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2832787 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
-1785645 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5815580 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19353691 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40500917 USD
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
5000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4749834 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5055000 USD
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3100000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
9229819 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
9229819 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16137661 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
841026 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-6587554 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12174614 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
380800 USD
CY2018Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2018Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one new share for every ten shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31545000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31545000 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25818495 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24269266 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, deferred compensation, valuation allowance for income tax assets and management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0001551986-18-000049-index-headers.html Edgar Link pending
0001551986-18-000049-index.html Edgar Link pending
0001551986-18-000049.txt Edgar Link pending
0001551986-18-000049-xbrl.zip Edgar Link pending
amarexfigure1a01.jpg Edgar Link pending
amarexfigure2a01.jpg Edgar Link pending
amarexlogoa01.jpg Edgar Link pending
ctrredactedversionama_image2.gif Edgar Link pending
ctrredactedversionama_image7.gif Edgar Link pending
ex101ctr-redactedversionxa.htm Edgar Link pending
ex102nedc9212018.htm Edgar Link pending
ex311q32018.htm Edgar Link pending
ex312q32018.htm Edgar Link pending
ex321q32018.htm Edgar Link pending
ex322q32018.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
innt-20180930.xml Edgar Link completed
innt-20180930.xsd Edgar Link pending
innt-20180930_cal.xml Edgar Link unprocessable
innt-20180930_def.xml Edgar Link unprocessable
innt-20180930_lab.xml Edgar Link unprocessable
innt-20180930_pre.xml Edgar Link unprocessable
innt930201810q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending